“With today’s approval, Calquence provides a critical new treatment option to mantle cell lymphoma patients in the US, with Calquence proven to deliver nearly one and a half years of ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

Sonrotoclax is under development for the treatment of relapsed and refractory multiple myeloma, B-cell malignancies such as nodal, extranodal, splenic marginal zone lymphoma, mantle cell lymphoma, ...

The agency also approved acalabrutinib as part of combination therapy for mantle cell lymphoma. The FDA approved two oncology regimens on Jan. 16. One is for a subset of patients with colorectal ...

Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma is currently unclear. (Funded by Johnson & Johnson and Legend Biotech USA ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The following is a summary of “Rapid Pleurodesis in Patients With Chronic Noninfectious Pleural Effusion,” published in the January 2025 issue of Pulmonology by Pu et al. Researchers conducted a ...

Primary effusion lymphoma (PEL) is an aggressive and rare type of diffuse large B-cell lymphoma (DLBL) that commonly presents itself as pleural, pericardial or peritoneal effusion without lymph node ...